EGFR and lung adenocarcinoma: In lung adenocarcinoma, mutation status of EV-associated DNA from pleural effusion correlated with cfDNA (Song et al., 2019), while presence of mutated EGFR informed about the EGFR tyrosine kinase inhibitor treatment efficacy (Qu et al., 2019).